{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:55:44Z","timestamp":1763564144166,"version":"3.40.5"},"reference-count":149,"publisher":"National Institute for Health and Care Research","issue":"17","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["14\/36\/02"],"award-info":[{"award-number":["14\/36\/02"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"Background<\/jats:title>Bisphosphonates are contraindicated in patients with stage 4+ chronic kidney disease. However, they are widely used to prevent fragility fractures in stage 3 chronic kidney disease, despite a lack of good-quality data on their effects.<\/jats:p><\/jats:sec>Objectives<\/jats:title>The aims of each work package were as follows. Work package 1: to study the relationship between bisphosphonate use and chronic kidney disease progression. Work package 2: to study the association between using bisphosphonates and fracture risk. Work package 3: to determine the risks of hypocalcaemia, hypophosphataemia, acute kidney injury and upper gastrointestinal events associated with using bisphosphonates. Work package 4: to investigate the association between using bisphosphonates and changes in bone mineral density over time.<\/jats:p><\/jats:sec>Design<\/jats:title>This was a new-user cohort study design with propensity score matching.<\/jats:p><\/jats:sec>Setting and data sources<\/jats:title>Data were obtained from UK NHS primary care (Clinical Practice Research Datalink GOLD database) and linked hospital inpatient records (Hospital Episode Statistics) for work packages 1\u20133 and from the Danish Odense University Hospital Databases for work package 4.<\/jats:p><\/jats:sec>Participants<\/jats:title>Patients registered in the data sources who had at least one measurement of estimated glomerular filtration rate of <\u200945\u2009ml\/minute\/1.73\u2009m2<\/jats:sup>were eligible. A second estimated glomerular filtration rate value of <\u200945\u2009ml\/minute\/1.73\u2009m2<\/jats:sup>within 1 year after the first was requested for work packages 1 and 3. Patients with no Hospital Episode Statistics linkage were excluded from work packages 1\u20133. Patients with <\u20091 year of run-in data before index estimated glomerular filtration rate and previous users of anti-osteoporosis medications were excluded from work packages 1\u20134.<\/jats:p><\/jats:sec>Interventions\/exposure<\/jats:title>Bisphosphonate use, identified from primary care prescriptions (for work packages 1\u20133) or pharmacy dispensations (for work package 4), was the main exposure.<\/jats:p><\/jats:sec>Main outcome measures<\/jats:title>Work package 1: chronic kidney disease progression, defined as stage worsening or starting renal replacement. Work package 2: hip fracture. Work package 3: acute kidney injury, hypocalcaemia and hypophosphataemia identified from Hospital Episode Statistics, and gastrointestinal events identified from Clinical Practice Research Datalink or Hospital Episode Statistics. Work package 4: annualised femoral neck bone mineral density percentage change.<\/jats:p><\/jats:sec>Results<\/jats:title>Bisphosphonate use was associated with an excess risk of chronic kidney disease progression (subdistribution hazard ratio 1.12, 95% confidence interval 1.02 to 1.24) in work package 1, but did not increase the probability of other safety outcomes in work package 3. The results from work package 2 suggested that bisphosphonate use increased fracture risk (hazard ratio 1.25, 95% confidence interval 1.13 to 1.39) for hip fractures, but sensitivity analyses suggested that this was related to unresolved confounding. Conversely, work package 4 suggested that bisphosphonates improved bone mineral density, with an average 2.65% (95% confidence interval 1.32% to 3.99%) greater gain in femoral neck bone mineral density per year in bisphosphonate users than in matched non-users.<\/jats:p><\/jats:sec>Limitations<\/jats:title>Confounding by indication was a concern for the clinical effectiveness (i.e. work package 2) data. Bias analyses suggested that these findings were due to inappropriate adjustment for pre-treatment risk. work packages 3 and 4 were based on small numbers of events and participants, respectively.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Bisphosphonates were associated with a 12% excess risk of chronic kidney disease progression in participants with stage 3B+ chronic kidney disease. No other safety concerns were identified. Bisphosphonate therapy increased bone mineral density, but the research team failed to demonstrate antifracture effectiveness.<\/jats:p><\/jats:sec>Future work<\/jats:title>Randomised controlled trial data are needed to demonstrate antifracture efficacy in patients with stage 3B+ chronic kidney disease. More safety analyses are needed to characterise the renal toxicity of bisphosphonates in stage 3A chronic kidney disease, possibly using observational data.<\/jats:p><\/jats:sec>Study registration<\/jats:title>This study is registered as EUPAS10029.<\/jats:p><\/jats:sec>Funding<\/jats:title>This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full inHealth Technology Assessment<\/jats:italic>; Vol. 25, No. 17. See the NIHR Journals Library website for further project information. The project was also supported by the National Institute for Health Research Biomedical Research Centre, Oxford.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta25170","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T16:43:21Z","timestamp":1616172201000},"page":"1-106","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study"],"prefix":"10.3310","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0940-9211","authenticated-orcid":true,"given":"Danielle E","family":"Robinson","sequence":"first","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, National Institute for Health Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4192-7908","authenticated-orcid":true,"given":"M Sanni","family":"Ali","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, National Institute for Health Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, UK"},{"name":"Faculty of Epidemiology and Population Health, Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5172-512X","authenticated-orcid":true,"given":"Victoria Y","family":"Strauss","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, National Institute for Health Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-1912","authenticated-orcid":true,"given":"Leena","family":"Elhussein","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, National Institute for Health Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2730-6080","authenticated-orcid":true,"given":"Bo","family":"Abrahamsen","sequence":"additional","affiliation":[{"name":"Open Patient data Explorative Network (OPEN), Department of Clinical Research, University of Southern Denmark, Odense, Denmark"},{"name":"Department of Medicine, Holb\u00e6k Hospital, Holb\u00e6k, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3452-3382","authenticated-orcid":true,"given":"Nigel K","family":"Arden","sequence":"additional","affiliation":[{"name":"Arthritis Research UK Sports, Exercise and Osteoarthritis Centre, University of Oxford, Oxford, UK"},{"name":"Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6648-3007","authenticated-orcid":true,"given":"Yoav","family":"Ben-Shlomo","sequence":"additional","affiliation":[{"name":"Population Health Sciences, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5199-3925","authenticated-orcid":true,"given":"Fergus","family":"Caskey","sequence":"additional","affiliation":[{"name":"School of Social and Community Medicine, University of Bristol, Bristol, UK"},{"name":"UK Renal Registry, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3510-0709","authenticated-orcid":true,"given":"Cyrus","family":"Cooper","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, National Institute for Health Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, UK"},{"name":"Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3699-5391","authenticated-orcid":true,"given":"Daniel","family":"Dedman","sequence":"additional","affiliation":[{"name":"Clinical Practice Research Datalink, Medicines and Healthcare products Regulatory Agency, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0388-3403","authenticated-orcid":true,"given":"Antonella","family":"Delmestri","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, National Institute for Health Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3015-0432","authenticated-orcid":true,"given":"Andrew","family":"Judge","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, National Institute for Health Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, UK"},{"name":"Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"},{"name":"National Institute for Health Research (NIHR) Bristol Biomedical Research Centre (BRC), University Hospitals Bristol NHS Foundation Trust, University of Bristol, Southmead Hospital, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-0048","authenticated-orcid":true,"given":"Muhammad Kassim","family":"Javaid","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, National Institute for Health Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, UK"},{"name":"Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-6346","authenticated-orcid":true,"given":"Daniel","family":"Prieto-Alhambra","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, National Institute for Health Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, UK"},{"name":"Grup de Recerca en Malalties Prevalents de l\u2019Aparell Locomotor (GREMPAL) Research Group and Centro de Investigaci\u00f3n Biom\u00e9dica en Red Fragilidad y Envejecimiento Saludable (CIBERFes), University Institute for Primary Care Research (IDIAP) Jordi Gol, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2021,3]]},"reference":[{"key":"key20210317145425237_ref1-bib1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","article-title":"Osteoporosis in the European Union: a compendium of country-specific reports","volume":"8","author":"Svedbom","year":"2013","journal-title":"Arch Osteoporos"},{"key":"key20210317145425237_ref1-bib2","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00198-014-2645-1","article-title":"Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005\u20132008: is treatment with bisphosphonates an option?","volume":"25","author":"Lubwama","year":"2014","journal-title":"Osteoporos Int"},{"key":"key20210317145425237_ref1-bib3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1093\/qjmed\/hcr122","article-title":"Chronic kidney disease prevalence and secular trends in a UK population: the impact of MDRD and CKD-EPI formulae","volume":"104","author":"Gifford","year":"2011","journal-title":"QJM"},{"key":"key20210317145425237_ref1-bib4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1053\/j.ajkd.2009.10.049","article-title":"Kidney function and rate of bone loss at the hip and spine: the Canadian Multicentre Osteoporosis Study","volume":"55","author":"Jamal","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"key20210317145425237_ref1-bib5","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1681\/ASN.2005111194","article-title":"Relationship between moderate to severe kidney disease and hip fracture in the United States","volume":"17","author":"Nickolas","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"key20210317145425237_ref1-bib6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1001\/archinte.167.2.133","article-title":"Renal function and risk of hip and vertebral fractures in older women","volume":"167","author":"Ensrud","year":"2007","journal-title":"Arch Intern Med"},{"key":"key20210317145425237_ref1-bib7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1053\/j.ajkd.2007.08.019","article-title":"Increased risk of hip fracture among men with CKD","volume":"51","author":"Dooley","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"key20210317145425237_ref1-bib8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","article-title":"Increased risk of hip fracture among patients with end-stage renal disease","volume":"58","author":"Alem","year":"2000","journal-title":"Kidney Int"},{"key":"key20210317145425237_ref1-bib9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/j.1445-5994.2007.01580.x","article-title":"Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid","volume":"38","author":"Chennuru","year":"2008","journal-title":"Intern Med J"},{"key":"key20210317145425237_ref1-bib10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3949\/ccjm.76a.08108","article-title":"Fragility fractures in chronic kidney disease: an opinion-based approach","volume":"76","author":"Miller","year":"2009","journal-title":"Cleve Clin J Med"},{"key":"key20210317145425237_ref1-bib11","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"key20210317145425237_ref1-bib12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00223-016-0141-7","article-title":"Real-life and RCT participants: alendronate users versus FITs\u2019 trial eligibility criterion","volume":"99","author":"Reyes","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"key20210317145425237_ref1-bib13","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1093\/ndt\/12.10.2144","article-title":"High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population","volume":"12","author":"Couttenye","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"key20210317145425237_ref1-bib14","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1681\/ASN.V1161093","article-title":"High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation","volume":"11","author":"Monier-Faugere","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"key20210317145425237_ref1-bib15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.semnephrol.2009.01.005","article-title":"Bone histomorphometry in renal osteodystrophy","volume":"29","author":"Ott","year":"2009","journal-title":"Semin Nephrol"},{"key":"key20210317145425237_ref1-bib16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.7326\/M16-2752","article-title":"Benefits and harms of osteoporosis medications in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"166","author":"Wilson","year":"2017","journal-title":"Ann Intern Med"},{"key":"key20210317145425237_ref1-bib17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial","volume":"22","author":"Jamal","year":"2007","journal-title":"J Bone Miner Res"},{"volume-title":"Raloxifene for the Primary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women","author":"National Institute for Health and Care Excellence","key":"key20210317145425237_ref1-bib18"},{"volume-title":"Raloxifene and Teriparatide for the Secondary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women","author":"National Institute for Health and Care Excellence","key":"key20210317145425237_ref1-bib19"},{"volume-title":"Fosamax Once Weekly 70\u2009mg Tablets: Summary of Product Characteristics","author":"Electronic Medicines Compendium","key":"key20210317145425237_ref1-bib20"},{"volume-title":"Bonviva 150\u2009mg Film-coated Tablets: Summary of Product Characteristics","author":"Electronic Medicines Compendium","key":"key20210317145425237_ref1-bib21"},{"volume-title":"Actonel 30\u2009mg Film-coated Tablets: Summary of Product Characteristics","author":"Electronic Medicines Compendium","key":"key20210317145425237_ref1-bib22"},{"key":"key20210317145425237_ref1-bib23","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-224068","article-title":"Denosumab causing severe, refractory hypocalcaemia in a patient with chronic kidney disease","volume":"2018","author":"Saleem","year":"2018","journal-title":"BMJ Case Rep"},{"key":"key20210317145425237_ref1-bib24","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.amjms.2017.09.008","article-title":"Denosumab-associated severe hypocalcemia in a patient with chronic kidney disease","volume":"355","author":"Salim","year":"2018","journal-title":"Am J Med Sci"},{"key":"key20210317145425237_ref1-bib25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.therap.2016.07.003","article-title":"Denosumab-induced severe hypocalcemia in a patient with Paget\u2019s disease of bone and impaired renal function","volume":"72","author":"Kostine","year":"2017","journal-title":"Therapie"},{"key":"key20210317145425237_ref1-bib26","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/pds.4045","article-title":"Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting","volume":"25","author":"Huynh","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20210317145425237_ref1-bib27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1053\/j.ajkd.2017.07.019","article-title":"KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"70","author":"Isakova","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"key20210317145425237_ref1-bib28","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.2169\/internalmedicine.8618-16","article-title":"Management of osteoporosis in chronic kidney disease","volume":"56","author":"Nitta","year":"2017","journal-title":"Intern Med"},{"key":"key20210317145425237_ref1-bib29","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"key":"key20210317145425237_ref1-bib30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.14236\/jhi.v19i3.811","article-title":"The history of the Read Codes: the inaugural James Read Memorial Lecture 2011","volume":"19","author":"Benson","year":"2011","journal-title":"Inform Prim Care"},{"issue":"28","key":"key20210317145425237_ref1-bib31","doi-asserted-by":"publisher","DOI":"10.3310\/hsdr04280","article-title":"Models of care for the delivery of secondary fracture prevention after hip fracture: a health service cost, clinical outcomes and cost-effectiveness study within a region of England","volume":"4","author":"Judge","year":"2016","journal-title":"Health Serv Deliv Res"},{"key":"key20210317145425237_ref1-bib32","doi-asserted-by":"publisher","first-page":"f6956","DOI":"10.1136\/bmj.f6956","article-title":"Primary hip replacement prostheses and their evidence base: systematic review of literature","volume":"347","author":"Kynaston-Pearson","year":"2013","journal-title":"BMJ"},{"key":"key20210317145425237_ref1-bib33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1471-2369-14-58","article-title":"The accuracy of diagnostic coding for acute kidney injury in England \u2013 a single centre study","volume":"14","author":"Tomlinson","year":"2013","journal-title":"BMC Nephrol"},{"key":"key20210317145425237_ref1-bib34","doi-asserted-by":"publisher","first-page":"c247","DOI":"10.1159\/000342857","article-title":"Chapter 13 The linkage of incident renal replacement therapy patients in England (2002\u20132006) to hospital episodes and national mortality data: improved demography and hospitalisation data in patients undergoing renal replacement therapy","volume":"120","author":"Fotheringham","year":"2012","journal-title":"Nephron Clin Pract"},{"edition":"10th","volume-title":"International Classification of Diseases","author":"World Health Organization","key":"key20210317145425237_ref1-bib35"},{"volume-title":"NHS Classifications OPCS-4","author":"NHS Digital","key":"key20210317145425237_ref1-bib36"},{"key":"key20210317145425237_ref1-bib37","doi-asserted-by":"publisher","first-page":"e110437","DOI":"10.1371\/journal.pone.0110437","article-title":"Duration of thyroid dysfunction correlates with all-cause mortality. the OPENTHYRO Register Cohort","volume":"9","author":"Laulund","year":"2014","journal-title":"PLOS ONE"},{"key":"key20210317145425237_ref1-bib38","unstructured":"European Union. Regulation (EU) 2016\/679 of the European Parliament and of the Council of 27 April 2016 on the Protection of Natural Persons with regard to the Processing of Personal Data and on the Free Movement of Such Data, and Repealing Directive 95\/46\/EC (General Data Protection Regulation) (OJ L 119 4.5.2016 p. 1\u201388). Brussels: European Union; 2016."},{"key":"key20210317145425237_ref1-bib39","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"key20210317145425237_ref1-bib40","doi-asserted-by":"publisher","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"L\u00e9vesque","year":"2010","journal-title":"BMJ"},{"key":"key20210317145425237_ref1-bib41","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/annrheumdis-2013-204043","article-title":"Hormone replacement therapy and mid-term implant survival following knee or hip arthroplasty for osteoarthritis: a population-based cohort study","volume":"74","author":"Prieto-Alhambra","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20210317145425237_ref1-bib42","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00198-012-2043-5","article-title":"Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose","volume":"24","author":"Vestergaard","year":"2013","journal-title":"Osteoporos Int"},{"key":"key20210317145425237_ref1-bib43","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1002\/art.38789","article-title":"Oral bisphosphonate use and total knee\/hip implant survival: validation of results in an external population-based cohort","volume":"66","author":"Prieto-Alhambra","year":"2014","journal-title":"Arthritis Rheum"},{"key":"key20210317145425237_ref1-bib44","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/aje\/kwi307","article-title":"Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods","volume":"162","author":"Zhou","year":"2005","journal-title":"Am J Epidemiol"},{"key":"key20210317145425237_ref1-bib45","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/fampra\/cmm026","article-title":"Kidney disease management in UK primary care: guidelines, incentives and information technology","volume":"24","author":"Klebe","year":"2007","journal-title":"Fam Pract"},{"key":"key20210317145425237_ref1-bib46","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"key20210317145425237_ref1-bib47","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/resp.12312","article-title":"Introduction to propensity scores","volume":"19","author":"Williamson","year":"2014","journal-title":"Respirology"},{"key":"key20210317145425237_ref1-bib48","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/pds.2074","article-title":"The role of the c-statistic in variable selection for propensity score models","volume":"20","author":"Westreich","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20210317145425237_ref1-bib49","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jclinepi.2007.07.011","article-title":"The performance of different propensity-score methods for estimating relative risks","volume":"61","author":"Austin","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"key20210317145425237_ref1-bib50","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","article-title":"Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance","volume":"17","author":"Nguyen","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"key20210317145425237_ref1-bib51","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"key20210317145425237_ref1-bib52","doi-asserted-by":"publisher","DOI":"10.1177\/0962280217713032","article-title":"Propensity score analysis with partially observed covariates: how should multiple imputation be used?","volume":"0","author":"Leyrat","year":"2017","journal-title":"Stat Methods Med Res"},{"key":"key20210317145425237_ref1-bib53","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1600-0773.1997.tb01964.x","article-title":"Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models","volume":"80","author":"Green","year":"1997","journal-title":"Pharmacol Toxicol"},{"key":"key20210317145425237_ref1-bib54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0300-483X(90)90088-X","article-title":"Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD), in rats and mice","volume":"65","author":"Cal","year":"1990","journal-title":"Toxicology"},{"key":"key20210317145425237_ref1-bib55","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0300-483X(78)90539-5","article-title":"Urinary gamma-glutamyl transferase in renal toxicology of the rat. Bases of its use and significance in acute mercurial nephritis","volume":"11","author":"Braun","year":"1978","journal-title":"Toxicology"},{"key":"key20210317145425237_ref1-bib56","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","article-title":"Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing","volume":"15","author":"Bauss","year":"2004","journal-title":"Osteoporos Int"},{"key":"key20210317145425237_ref1-bib57","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1742-7843.2005.pto_160.x","article-title":"Acute renal effects of intravenous bisphosphonates in the rat","volume":"97","author":"Pfister","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"key20210317145425237_ref1-bib58","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"Markowitz","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"key20210317145425237_ref1-bib59","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1523-1755.2004.00426.x","article-title":"Podocyte injury associated glomerulopathies induced by pamidronate","volume":"65","author":"Barri","year":"2004","journal-title":"Kidney Int"},{"key":"key20210317145425237_ref1-bib60","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1046\/j.1365-2141.2002.03826.x","article-title":"Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma","volume":"119","author":"Desikan","year":"2002","journal-title":"Br J Haematol"},{"key":"key20210317145425237_ref1-bib61","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/08998280.2007.11928298","article-title":"Reversibility of pamidronate-associated glomerulosclerosis","volume":"20","author":"Shreedhara","year":"2007","journal-title":"Proc"},{"key":"key20210317145425237_ref1-bib62","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1053\/ajkd.2002.32797","article-title":"Nephrotic syndrome after treatment with pamidronate","volume":"39","author":"Markowitz","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"key20210317145425237_ref1-bib63","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/ndt\/gfg567","article-title":"Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient","volume":"19","author":"Kunin","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"key20210317145425237_ref1-bib64","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.1053\/ajkd.2002.33933","article-title":"Pamidronate-associated nephrotoxicity in a patient with Langerhans\u2019s histiocytosis","volume":"40","author":"Lockridge","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"key20210317145425237_ref1-bib65","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/sj.ki.5000144","article-title":"Multiple myeloma, nephrotic syndrome and crystalloid inclusions in podocytes","volume":"69","author":"Nasr","year":"2006","journal-title":"Kidney Int"},{"key":"key20210317145425237_ref1-bib66","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1093\/ndt\/gfm209","article-title":"Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient","volume":"22","author":"Bodmer","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"key20210317145425237_ref1-bib67","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"key20210317145425237_ref1-bib68","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"key20210317145425237_ref1-bib69","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"key20210317145425237_ref1-bib70","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"key20210317145425237_ref1-bib71","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial \u2013 the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20210317145425237_ref1-bib72","doi-asserted-by":"publisher","first-page":"a257","DOI":"10.1136\/bmj.a257","article-title":"Collaboration. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial","volume":"337","author":"Nunn","year":"2008","journal-title":"BMJ"},{"key":"key20210317145425237_ref1-bib73","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000362695","article-title":"Modelling childhood growth using fractional polynomials and linear splines","volume":"65","author":"Tilling","year":"2014","journal-title":"Ann Nutr Metab"},{"key":"key20210317145425237_ref1-bib74","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"key20210317145425237_ref1-bib75","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/003591576505800503","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"},{"key":"key20210317145425237_ref1-bib76","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/pds.1200","article-title":"Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics","volume":"15","author":"Schneeweiss","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20210317145425237_ref1-bib77","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00198-012-2068-9","article-title":"Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis","volume":"24","author":"Freemantle","year":"2013","journal-title":"Osteoporos Int"},{"key":"key20210317145425237_ref1-bib78","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/jgs.14668","article-title":"Osteoporosis treatment efficacy for men: a systematic review and meta-analysis","volume":"65","author":"Nayak","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"key20210317145425237_ref1-bib79","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/jbmr.2058","article-title":"Renal safety in patients treated with bisphosphonates for osteoporosis: a review","volume":"28","author":"Miller","year":"2013","journal-title":"J Bone Miner Res"},{"key":"key20210317145425237_ref1-bib80","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"key20210317145425237_ref1-bib81","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"key20210317145425237_ref1-bib82","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/jbmr.2882","article-title":"Anti-osteoporosis medication prescriptions and incidence of subsequent fracture among primary hip fracture patients in England and Wales: an interrupted time-series analysis","volume":"31","author":"Hawley","year":"2016","journal-title":"J Bone Miner Res"},{"key":"key20210317145425237_ref1-bib83","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.kint.2017.07.021","article-title":"Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation","volume":"92","author":"Pimentel","year":"2017","journal-title":"Kidney Int"},{"key":"key20210317145425237_ref1-bib84","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"key20210317145425237_ref1-bib85","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/rheumatology\/ket236","article-title":"Safety issues with bisphosphonate therapy for osteoporosis","volume":"53","author":"Suresh","year":"2014","journal-title":"Rheumatology"},{"key":"key20210317145425237_ref1-bib86","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2165\/11585470-000000000-00000","article-title":"Safety of long-term bisphosphonate therapy for the management of osteoporosis","volume":"71","author":"Lewiecki","year":"2011","journal-title":"Drugs"},{"key":"key20210317145425237_ref1-bib87","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"key20210317145425237_ref1-bib88","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1345\/aph.1E589","article-title":"Zoledronic acid and renal toxicity: data from French adverse effect reporting database","volume":"39","author":"Munier","year":"2005","journal-title":"Ann Pharmacother"},{"key":"key20210317145425237_ref1-bib89","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.1016\/S0272-6386(03)00214-2","article-title":"Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity","volume":"41","author":"Banerjee","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"key20210317145425237_ref1-bib90","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/ki.1996.380","article-title":"Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group","volume":"50","author":"Lia\u00f1o","year":"1996","journal-title":"Kidney Int"},{"key":"key20210317145425237_ref1-bib91","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1302\/0301-620X.98B8.37497","article-title":"Risk of acute renal failure and mortality after surgery for a fracture of the hip: a population-based cohort study","volume":"98\u2013B","author":"Pedersen","year":"2016","journal-title":"Bone Joint J"},{"key":"key20210317145425237_ref1-bib92","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1001\/archinte.160.4.517","article-title":"Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial","volume":"160","author":"Bauer","year":"2000","journal-title":"Arch Intern Med"},{"key":"key20210317145425237_ref1-bib93","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00198-014-2647-z","article-title":"Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study","volume":"25","author":"Peng","year":"2014","journal-title":"Osteoporos Int"},{"key":"key20210317145425237_ref1-bib94","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.amjmed.2008.12.004","article-title":"Safety of bisphosphonates in the treatment of osteoporosis","volume":"122","author":"Recker","year":"2009","journal-title":"Am J Med"},{"key":"key20210317145425237_ref1-bib95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000362374","article-title":"Front & Back Matter","volume":"125","author":"UK Renal Registry","year":"2013","journal-title":"Nephron Clinical Practice"},{"volume-title":"European Program of Post-Authorization Safety Studies for Protelos\u00ae\/Osseor\u00ae through EU-ADR Alliance","author":"Nuffield Department of Orthopaedics, Rhuematology and Musculoskeletal Sciences","key":"key20210317145425237_ref1-bib96"},{"key":"key20210317145425237_ref1-bib97","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/0140-6736(93)92555-8","article-title":"Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group","volume":"341","author":"Cummings","year":"1993","journal-title":"Lancet"},{"key":"key20210317145425237_ref1-bib98","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/jbmr.2406","article-title":"Bone mineral density predicts fractures in chronic kidney disease","volume":"30","author":"West","year":"2015","journal-title":"J Bone Miner Res"},{"key":"key20210317145425237_ref1-bib99","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","article-title":"Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group","volume":"42","author":"Hochberg","year":"1999","journal-title":"Arthritis Rheum"},{"key":"key20210317145425237_ref1-bib100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF03339822","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging"},{"key":"key20210317145425237_ref1-bib101","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"key":"key20210317145425237_ref1-bib102","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"key20210317145425237_ref1-bib103","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1001\/jama.283.10.1318","article-title":"Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group","volume":"283","author":"Cummings","year":"2000","journal-title":"JAMA"},{"key":"key20210317145425237_ref1-bib104","doi-asserted-by":"publisher","first-page":"3485785","DOI":"10.1155\/2017\/3485785","article-title":"Molecular abnormalities underlying bone fragility in chronic kidney disease","volume":"2017","author":"Iwasaki","year":"2017","journal-title":"Biomed Res Int"},{"key":"key20210317145425237_ref1-bib105","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1056\/NEJM199003223221203","article-title":"Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis","volume":"322","author":"Riggs","year":"1990","journal-title":"N Engl J Med"},{"key":"key20210317145425237_ref1-bib106","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12882-015-0182-6","article-title":"Comparison of single CT scan assessment of bone mineral density, vascular calcification and fat mass with standard clinical measurements in renal transplant subjects: the ABC HeART study","volume":"16","author":"Kinsella","year":"2015","journal-title":"BMC Nephrol"},{"key":"key20210317145425237_ref1-bib107","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/jbmr.2244","article-title":"Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures-the OPENTHYRO register cohort","volume":"29","author":"Abrahamsen","year":"2014","journal-title":"J Bone Miner Res"},{"key":"key20210317145425237_ref1-bib108","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/jbmr.2416","article-title":"The excess risk of major osteoporotic fractures in hypothyroidism is driven by cumulative hyperthyroid as opposed to hypothyroid time: an observational register-based time-resolved cohort analysis","volume":"30","author":"Abrahamsen","year":"2015","journal-title":"J Bone Miner Res"},{"key":"key20210317145425237_ref1-bib109","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3945\/ajcn.116.145599","article-title":"Neonatal vitamin D status from archived dried blood spots and future risk of fractures in childhood: results from the D-tect study, a population-based case-cohort study","volume":"106","author":"H\u00e4ndel","year":"2017","journal-title":"Am J Clin Nutr"},{"key":"key20210317145425237_ref1-bib110","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/2151458516647989","article-title":"Low levels of hemoglobin at admission are associated with increased 30-day mortality in patients with hip fracture","volume":"7","author":"Praetorius","year":"2016","journal-title":"Geriatr Orthop Surg Rehabil"},{"key":"key20210317145425237_ref1-bib111","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/jbmr.2737","article-title":"Fracture risk is decreased in women with polycystic ovary syndrome: a register-based and population-based cohort study","volume":"31","author":"Rubin","year":"2016","journal-title":"J Bone Miner Res"},{"key":"key20210317145425237_ref1-bib112","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11657-020-00746-z","article-title":"Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B\u20135) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark","volume":"15","author":"Sanni Ali","year":"2020","journal-title":"Arch Osteoporos"},{"volume-title":"Guide on Methodological Standards in Pharmacoepidemiology (Revision 5). EMA\/95098\/2010","author":"The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)","key":"key20210317145425237_ref1-bib113"},{"key":"key20210317145425237_ref1-bib114","first-page":"322","article-title":"Primary care prescriptions and subsequent pharmacy dispensing: a population-based study","volume":"23","author":"Prieto-Alhambra","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20210317145425237_ref1-bib115","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.kint.2016.04.010","article-title":"Methodological challenges when carrying out research on CKD and AKI using routine electronic health records","volume":"90","author":"McDonald","year":"2016","journal-title":"Kidney Int"},{"key":"key20210317145425237_ref1-bib116","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/0895-4356(94)90170-8","article-title":"Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research","volume":"47","author":"Moride","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"key20210317145425237_ref1-bib117","doi-asserted-by":"publisher","first-page":"k119","DOI":"10.1136\/bmj.k119","article-title":"Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study","volume":"360","author":"Patorno","year":"2018","journal-title":"BMJ"},{"key":"key20210317145425237_ref1-bib118","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1111\/j.1600-6143.2012.04233.x","article-title":"A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation","volume":"12","author":"Smerud","year":"2012","journal-title":"Am J Transplant"},{"key":"key20210317145425237_ref1-bib119","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1097\/TP.0b013e3181dc13d0","article-title":"Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients","volume":"89","author":"Torregrosa","year":"2010","journal-title":"Transplantation"},{"key":"key20210317145425237_ref1-bib120","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1053\/j.ajkd.2008.11.036","article-title":"Effect of pamidronate on bone loss after kidney transplantation: a randomized trial","volume":"53","author":"Walsh","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"key20210317145425237_ref1-bib121","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.ajkd.2009.12.039","article-title":"Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial","volume":"56","author":"Toussaint","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"key20210317145425237_ref1-bib122","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","article-title":"Imminent risk of fracture after fracture","volume":"28","author":"Johansson","year":"2017","journal-title":"Osteoporos Int"},{"key":"key20210317145425237_ref1-bib123","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"key20210317145425237_ref1-bib124","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/1099-1557(200009\/10)9:5<359::AID-PDS507>3.0.CO;2-E","article-title":"The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results","volume":"9","author":"Van Staa","year":"2000","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20210317145425237_ref1-bib125","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/art.30214","article-title":"Fracture risk before and after total hip replacement in patients with osteoarthritis: potential benefits of bisphosphonate use","volume":"63","author":"Prieto-Alhambra","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key20210317145425237_ref1-bib126","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1136\/ard.2010.131110","article-title":"Changes in hip fracture rate before and after total knee replacement due to osteoarthritis: a population-based cohort study","volume":"70","author":"Prieto-Alhambra","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20210317145425237_ref1-bib127","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"issue":"78","key":"key20210317145425237_ref1-bib128","doi-asserted-by":"publisher","DOI":"10.3310\/hta20780","article-title":"A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures","volume":"20","author":"Davis","year":"2016","journal-title":"Health Technol Assess"},{"key":"key20210317145425237_ref1-bib129","doi-asserted-by":"publisher","first-page":"i3365","DOI":"10.1136\/bmj.i3365","article-title":"Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study","volume":"353","author":"Abrahamsen","year":"2016","journal-title":"BMJ"},{"key":"key20210317145425237_ref1-bib130","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s00198-010-1368-1","article-title":"Bisphosphonate use and risk of post-operative fracture among patients undergoing a total knee replacement for knee osteoarthritis: a propensity score analysis","volume":"22","author":"Prieto-Alhambra","year":"2011","journal-title":"Osteoporos Int"},{"key":"key20210317145425237_ref1-bib131","doi-asserted-by":"publisher","first-page":"e002084","DOI":"10.1136\/bmjopen-2012-002084","article-title":"Oral bisphosphonates may not decrease hip fracture risk in elderly Spanish women: a nested case-control study","volume":"3","author":"Erviti","year":"2013","journal-title":"BMJ Open"},{"key":"key20210317145425237_ref1-bib132","doi-asserted-by":"publisher","first-page":"e0118178","DOI":"10.1371\/journal.pone.0118178","article-title":"Use of oral bisphosphonates in primary prevention of fractures in postmenopausal women: a population-based cohort study","volume":"10","author":"Real","year":"2015","journal-title":"PLOS ONE"},{"key":"key20210317145425237_ref1-bib133","unstructured":"He Y, Reyes C, Lapi F, Simonetti M, Rijnbeek P, Van der Lei J et al. A multi-database, multinational validation study of cardiovascular death, venous thromboembolic events and gastrointestinal diseases in the EU-ADR Alliance. International Society for Pharmaeconomics and Outcomes Research (ISPOR) Europe, Barcelona, Spain, November 2018."},{"key":"key20210317145425237_ref1-bib134","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1200\/JOP.2011.000486","article-title":"Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project","volume":"9","author":"Edwards","year":"2013","journal-title":"J Oncol Pract"},{"key":"key20210317145425237_ref1-bib135","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.2169\/internalmedicine.52.0094","article-title":"Acute kidney injury in a patient with nephrotic syndrome due to focal segmental glomerular nephritis induced by a single oral administration of high-dose bisphosphonate (minodronate)","volume":"52","author":"Komada","year":"2013","journal-title":"Intern Med"},{"key":"key20210317145425237_ref1-bib136","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1081\/JDI-65397","article-title":"Acute granulomatous interstitial nephritis secondary to bisphosphonate alendronate sodium","volume":"27","author":"Pe\u00f1a de la Vega","year":"2005","journal-title":"Ren Fail"},{"key":"key20210317145425237_ref1-bib137","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/ki.2012.227","article-title":"Oral bisphosphonate use in the elderly is not associated with acute kidney injury","volume":"82","author":"Shih","year":"2012","journal-title":"Kidney Int"},{"key":"key20210317145425237_ref1-bib138","first-page":"184","article-title":"The effect of oral bisphosphonates on acute kidney injury, gastrointestinal events and hypocalcaemia in patients with chronic kidney disease","volume":"27","author":"Ali","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20210317145425237_ref1-bib139","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2009.188","article-title":"Kidney Disease: Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"188","author":"Moe","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"key20210317145425237_ref1-bib140","doi-asserted-by":"publisher","first-page":"w13979","DOI":"10.4414\/smw.2014.13979","article-title":"Bisphosphonate induced hypocalcaemia \u2013 report of six cases and review of the literature","volume":"144","author":"Kreutle","year":"2014","journal-title":"Swiss Med Wkly"},{"key":"key20210317145425237_ref1-bib141","doi-asserted-by":"publisher","first-page":"139","DOI":"10.11005\/jbm.2012.19.2.139","article-title":"Bisphosphonate-induced severe hypocalcemia \u2013 a case report","volume":"19","author":"Do","year":"2012","journal-title":"J Bone Metab"},{"key":"key20210317145425237_ref1-bib142","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.amjopharm.2012.04.001","article-title":"Effects of oral bisphosphonate therapy on serum calcium in elderly veterans with poor kidney function","volume":"10","author":"Vouri","year":"2012","journal-title":"Am J Geriatr Pharmacother"},{"key":"key20210317145425237_ref1-bib143","doi-asserted-by":"publisher","first-page":"b2266","DOI":"10.1136\/bmj.b2266","article-title":"Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data","volume":"338","author":"Bell","year":"2009","journal-title":"BMJ"},{"key":"key20210317145425237_ref1-bib144","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"key20210317145425237_ref1-bib145","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00198-010-1348-5","article-title":"Prevalence of risk factors for fractures and use of DXA scanning in Danish women. A regional population-based study","volume":"22","author":"Rubin","year":"2011","journal-title":"Osteoporos Int"},{"key":"key20210317145425237_ref1-bib146","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s001980070122","article-title":"Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients","volume":"11","author":"Eastell","year":"2000","journal-title":"Osteoporos Int"},{"key":"key20210317145425237_ref1-bib147","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"key20210317145425237_ref1-bib148","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"key":"key20210317145425237_ref1-bib149","first-page":"185","article-title":"Oral bisphosphonate use and all-cause mortality in patients with advanced (stage IIIB+) chronic kidney disease: a propensity score analysis","volume":"27","author":"Alarkawi","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2036205","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta25170\/hta25170.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2036205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:38:03Z","timestamp":1692113883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta25170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":149,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["10.3310\/hta25170"],"URL":"https:\/\/doi.org\/10.3310\/hta25170","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"type":"print","value":"1366-5278"},{"type":"electronic","value":"2046-4924"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"12-2015","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"10-2018","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"3-2019","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}